New Oral Anticoagulants (NOAC) in Stroke Patients
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Jan 31, 2019
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre. Special interest is payed to conditions not or only in part investigated in the large randomised controlled Trials (RCT) and that are specific to patients with cerebrovascular disease. This includes early start of NOAC treatment after recent stroke, very old patients, multimorbidity, patients with a history of intracranial haemorrhage (I...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • signed informed consent form (ICF)
- • existing or newly diagnosed AF
- • recent (\< 3 month) stroke (ischemic or haemorrhagic) or TIA (=index event)
- • treatment with NOACs or VKAs is continued, changed or initiated for prevention of ischemic events
- Exclusion Criteria:
- • patients not able or unwilling to sign ICF
- • patient is, in the opinion of the investigator, unlikely to comply with the scheduled follow-up visits or is unsuitable for any other reason
- • patients who will not be anticoagulated
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Basel, , Switzerland
Patients applied
Trial Officials
Philippe Lyrer, Prof. Dr. MD
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials